This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Borg S, Ericsson Å.Budesonide/formoterol is more cost-effective than salmeterol/fluticasone in severe COPD: a Markov model simulation. European Respiratory Journal Supplement 28 (Suppl. 50): 738, Sep 2006
Dal Negro RW, Iannazzo S, Pradelli L, Eandi M.The therapeutic strategies in severe and very severe COPD: a cost-efficacy analysis in Italy. European Respiratory Journal Supplement 28 (Suppl. 50): 31, Sep 2006
Price D, Wiren A, Kuna P.Budesonide/formoterol (B/F) as maintenance and relief for asthma improves efficacy and is cost-saving versus a higher maintenance dose of B/F or salmeterol/fluticasone. European Respiratory Journal Supplement 28 (Suppl. 50): 214, Sep 2006
Vorobyev PA, Aksentyeva MV, Smirnova MS.Cost-effectiveness of budsonide/formoterol inhaler in treatment of moderate bronchial asthma. European Respiratory Journal Supplement 28 (Suppl. 50): 499, Sep 2006
Rights and permissions
About this article
Cite this article
Budesonide/formoterol makes cents in COPD, asthma. Pharmacoecon. Outcomes News 514, 3–4 (2006). https://doi.org/10.2165/00151234-200605140-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605140-00006